Law Updates

The Ministry of Power has granted Section 164 authorization under the Electricity Act, 2003, to Project Nine Renewable Power Private Limited. This approval allows the company to lay overhead transmission lines for its 450 MW solar project in Jodhpur, Rajasthan.

The order empowers the company with the same rights as a telegraph authority under the Indian Telegraph Act, 1885, for laying electric lines. The authorization remains valid for 25 years, provided that several compliance conditions are met.

Project Nine must get approvals from local bodies, railways, and highway authorities before construction. It must also follow Central Government inspection norms, seek civil aviation and defence clearances, and comply with the Supreme Court’s directives on the Great Indian Bustard protection.

This move reinforces India’s renewable power infrastructure and supports the government’s commitment to sustainable energy expansion across key solar zones in Rajasthan.

The Central Government has notified the Companies (Meetings of Board and its Powers) Amendment Rules, 2025, which update the 2014 Rules under the Companies Act, 2013. This amendment revises Rule 11 to clearly define the term “business of financing industrial enterprises” under Section 186(11)(a) of the Act. 

For Non-Banking Financial Companies (NBFCs) registered with the Reserve Bank of India, the definition now includes giving loans or providing guarantees or security for loan repayments in the normal course of business. For finance companies registered with the International Financial Services Centres Authority (IFSCA), it includes these activities and other financial services allowed under the IFSCA (Finance Company) Regulations, 2021. 

This clarification helps companies, directors, and regulators understand which financial activities Section 186 covers, ensuring smoother compliance and better corporate governance, covers. The amendment brings consistency between the Companies Act and financial regulatory frameworks, strengthening oversight on company loans, guarantees, and investment decisions.

The Ministry of Chemicals and Fertilizers, through the Department of Pharmaceuticals, released an addendum on 4th November 2025. The National Pharmaceutical Pricing Authority (NPPA) updated its earlier orders related to the ceiling price fixation of scheduled IV fluid formulations with special features. This new order adds five manufacturers and marketers to Table B under the existing NPPA order. 

The new entries include IV Tech Healthcare, Safal Lifescience Pvt. Ltd., One Drip Healthcare Pvt. Ltd., Life Infusion Pharmaceuticals Pvt. Ltd., Virchow Biotech Pvt. Ltd., Klokter Life Sciences Pvt. Ltd., and Zee Laboratories Ltd. Each company has been assigned specific applicable formulations from Table A, defining which IV fluid variants fall under NPPA’s controlled pricing. Clauses (h5) to (h8) specify these details, ensuring that only certain formulations are subject to the notified ceiling prices. 

For instance, IV Tech Healthcare and Life Infusion Pharmaceuticals can apply ceiling prices only for formulations at serial numbers 1, 2, 3, 4, 5, 7, and 8. Similarly, Virchow Biotech, Safal Lifescience, and Klokter Life Sciences have defined applicable formulations based on their product categories. This NPPA update ensures uniform pricing and transparency across the pharmaceutical market, preventing overpricing of essential IV fluids and promoting fair access to life-saving medicines in India.

The National Pharmaceutical Pricing Authority (NPPA) has issued an update to its earlier Gazette notifications, 3000(E) dated July 4, 2025, and 3977(E) dated August 29, 2025, concerning the ceiling price fixation of scheduled I.V. fluid formulations (non-glass with special features). The update introduces four new clauses: (h5), (h6), (h7), and (h8).

Under clause (h5), for M/s IV Tech Healthcare and M/s Life Infusion Pharmaceuticals Pvt. Ltd., only formulations listed at Serial Numbers 1, 2, 3, 4, 5, 7, and 8 of Table A are covered. Clause (h6) applies to M/s Safal Lifescience Pvt. Ltd. and M/s One Drip Healthcare Pvt. Ltd., limiting applicable formulations to Serial Numbers 2, 4, 5, and 7. Clause (h7) specifies that for M/s Virchow Biotech Pvt. Ltd., formulations under Serial Numbers 1, 2, 4, 5, 6, 7, and 8 are valid. Clause (h8) states that M/s Klokter Life Sciences Pvt. Ltd. and M/s Zee Laboratories Ltd. are covered only for formulations numbered 2, 4, and 7.

These additions strengthen compliance and bring greater clarity to price applicability.

The National Pharmaceutical Pricing Authority (NPPA) has issued a new order under the Drugs (Prices Control) Order, 2013, fixing retail prices for certain new drug formulations. Manufacturers are directed to set retail prices as mentioned in the official table and may add GST only if it is actually payable to the government.

As per DPCO provisions, manufacturers must issue a price list in Form V and submit it through IPDMS, along with copies to the State Drug Controller and dealers. Retailers and dealers are required to display the approved price list and any supplementary lists prominently at their business premises.

The fixed retail price applies only to manufacturers or marketers who have obtained approval through Form I and hold valid manufacturing licenses. Any violation or overcharging will require repayment with interest under DPCO 2013 and the Essential Commodities Act, 1955. Earlier price orders for the same formulations stand superseded following this notification.

The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has issued a new order on November 4, 2025, revising the ceiling prices of several key medicines under the Drugs (Prices Control) Order, 2013 (DPCO 2013). The updated list includes Riboflavin tablets (10mg), Peritoneal dialysis solution, Ethyl alcohol (70%), and Human Normal Immunoglobulin in various strengths. 

The revised ceiling prices range from 0.22 to 478.57 rupees per unit, excluding Goods and Services Tax (GST). Manufacturers selling these scheduled formulations must ensure that their prices do not exceed the fixed ceiling price plus applicable GST. If a manufacturer’s existing price is lower than the new ceiling, it must remain unchanged. Manufacturers are also required to submit updated price lists in Form-V through the Integrated Pharmaceutical Database Management System (IPDMS) and share copies with the State Drug Controllers and dealers. Retailers must display the price lists prominently for public access. 

The order also mandates quarterly production and sales returns in Form-III and prior intimation for any discontinuation of products. Non-compliance with these provisions will result in the recovery of overcharged amounts, along with interest, under the Essential Commodities Act, 1955. The revised prices replace previous price orders to maintain uniformity, affordability, and transparency in pharmaceutical pricing across India. This move by NPPA ensures fair pricing of essential medicines, strengthens consumer protection, and reinforces government efforts to make vital drugs accessible and affordable for all citizens.